Main menu


Albireo Pharma (ALBO) Appoints Habib Dable and Susan Alesina to Board of Directors

featured image

Get instant alerts when news hits your stock. Claim your 1 week free trial Street Insider Premium here.

Albireo Pharma, Inc. (Nasdaq: ALBO) today announced the appointment of Habib Dable and Susan Alesina to its Board of Directors. The two are seasoned strategic leaders with extensive pharmaceutical and biotechnology expertise in business development, operations and commercialization. These additions are exciting as Albireo continues to achieve clinical, regulatory and commercial milestones for his Bylvay® (odevixibat) and advance additional investigational compounds for adult liver and viral diseases indicates the right time.

Dr. David Chiswell, Chairman of Albireo’s Board of Directors, said: “Habib brings extensive global business and commercial experience across pharmaceutical and biotechnology drug classes and therapeutic areas that will be critical in our next phase of growth. Susan Strategic Planning and Business Development Her expertise in pediatric patients with rare diseases is important as we develop and expand our pipeline, and she advocates for access to pediatric patients with rare diseases as we continue to maintain our patient-first mission at the forefront of our business. The insight and experience of

Mr. Dable is a multi-talented, patient-focused executive with nearly 28 years of experience in “big pharma” and “emerging biotech” environments, and is currently an independent director of Blueprint Medicines Corporation and a non-executive venture partner at RA Ventures. is. Most recently, Dable said he’s a biopharmaceutical company targeting cutting-edge treatments for patients with serious and rare diseases, until he’s sold to Merck for $11.5 billion in 2021. Previously served as President and CEO of Acceleron Pharma Inc. Before joining Acceleron in 2016, Dable worked for Bayer AG for 22 years. During his tenure at Bayer, Mr. Dable held a series of high-profile positions, including president of the U.S. Pharmaceutical Division, vice president and global head of the Specialty Medicine Division. Mr. Dable led the launch of various blockbuster brands including EYLEA®, Stivarga® and Xofigo®. Mr. Dable is a former board member of the Biotechnology Innovation Organization (BIO) and a former independent director of Millendo Therapeutics. Mr. Dable holds a master’s and bachelor’s degree in business administration from the University of New Brunswick and completed his executive program at the Stanford University Graduate School of Business.

“We are delighted to contribute to the progress of this innovative company. We truly believe that Albireo has the opportunity to provide life-changing treatments to patients suffering from liver disease around the world, and we believe in its compelling We look forward to supporting the advancement of the scientific pipeline.”

Alesina has over 25 years of management experience in pharmaceutical, biotech and medical device organizations. Throughout her career, she held senior positions in strategic planning and analysis, business development, and communications. She currently serves as Vice President of National Business Development and Alliances for Boston Children’s Hospital, working strategically with the nation’s healthcare system and hospital providers to improve access to pediatric patients with rare and complex conditions. Leads efforts to identify and develop partnerships. She previously worked at Millipore where she was a partner at Sigma where she was a global head of communications and prior to that a pharmaceutical company where she was a consultant and Sunovion where she worked as a corporate planning and pharmaceutical company. He held various leadership roles in communications. Alesina supported the launch of blockbuster products such as Lunesta® and her Latuda®. Alesina is a former director and president of the Association’s Boston chapter. She currently serves on the Board of Directors of the HBS Healthcare Alumni Association. Alesina received her undergraduate degree from the University of North Carolina at Chapel Hill and her MBA from Harvard Business School.

Susan Alesina says: “I look forward to using my experience in strategic planning, business development and communications to contribute to the continued success of the company.”